TTNP : Summary for Titan Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 1 hr 16 mins

Titan Pharmaceuticals, Inc. (TTNP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.20-0.05 (-1.18%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4.25
Bid3.55 x 2000
Ask4.35 x 400
Day's Range4.20 - 4.35
52 Week Range2.57 - 8.74
Avg. Volume132,110
Market Cap89.04M
PE Ratio (TTM)16.73
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire18 days ago

    Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year

    Sheldon is committed to bringing innovative, new treatment options to treat chronic diseases shrouded in stigma, such as opioid dependence, pain and schizophrenia. Braeburn is focused on serving patients suffering from health conditions where there has been little innovation in recent years. Gold award winner Probuphine is a six-month buprenorphine implant for the maintenance treatment of opioid addiction.

  • Zacks Small Cap Research18 days ago

    TTNP: Training Providers and Securing Payors; 3Q:16 Results

    Titan Pharmaceuticals, Inc. (TTNP) reported 3Q:16 results on November 9, 2016.  Total revenues, which consisted entirely of Probuphine royalties were $26,000, which compares to royalty revenues of $4,000 in the prior quarter and $0 in 3Q:15.  The result was behind our estimates of $350,000.  Titan cited paperwork and administrative burden as a primary reason for the slower than expected ramp up in sales.  Loss per share was ($0.12) compared to our estimate of ($0.11) and third quarter 2015 loss per share of ($0.09).  Our estimate and actual earnings per share varied due to lower than expected revenues and higher R&D costs partially offset by lower G&A expense. Research and development expenditures were $1.6 million for the quarter, up from $1.0 million in the prior year and above our estimate of $1.4 million.  Higher R&D was attributable to greater external R&D expenses related to ProNeura development and employee expenses.  Reimbursement from partner Braeburn reduced the amount by $0.4 million.  General and administrative expenditures were $1.1 million, up $0.3 million compared to last year’s spend.  This was lower than our $1.2 million estimate.  The year over year increase was related to higher non-cash stock compensation of $0.1 million and professional fees of $0.2 million.   Net other expense of $4,000 consisted primarily of non-cash gains and losses on changes in the fair value of warrants.

  • Associated Presslast month

    Titan Pharmaceuticals reports 3Q loss

    The South San Francisco, California-based company said it had a loss of 12 cents per share. The specialty pharmaceutical company posted revenue of $26,000 in the period. The company's shares closed at ...